研究单位:[1]Chipscreen Biosciences, Ltd.[2]Peking University People's Hospital[3]Hefei Second People's Hospital,Hefei, Anhui, China[4]The First Affiliated Hospital of Anhui Medical University,Hefei, Anhui, China[5]The Second Affiliated Hospital of Anhui Medical University,Hefei, Anhui, China[6]Yijishan Hospital of Wannan Medical College,Wuhu, Anhui, China[7]Beijing Chaoyang Hospital, Capital Medical University,Beijing, Beijing, China[8]Beijing Friendship Hospital, Capital Medical University,Beijing, Beijing, China[9]Beijing Luhe Hospital, Capital Medical University,Beijing, Beijing, China[10]Beijing Tongren Hospital, Capital Medical University,Beijing, Beijing, China[11]Beijing Tsinghua Chang Gung Memorial Hospital,Beijing, Beijing, China[12]Beijing University First Hospital,Beijing, Beijing, China[13]Chinese People's Liberation Army Rocket Army Characteristic Medical Center,Beijing, Beijing, China[14]Peking University People's Hospital,Beijing, Beijing, China[15]Xuanwu Hospital, Capital Medical University,Beijing, Beijing, China[16]The Second Affiliated Hospital of Chongqing Medical University,Chongqing, Chongqing, China[17]Three Gorges Hospital Affiliated to Chongqing University,Wanzhou, Chongqing, China[18]Shenzhen People's Hospital,Shenzhen, Guangdong, China[19]Union Shenzhen Hospital of Huazhong University of Science and Technology,Shenzhen, Guangdong, China[20]Harrison International Peace Hospital,Hengshui, Hebei, China[21]The Second Hospital of Hebei Medical University,Shijia Zhuang, Hebei, China[22]The Third Hospital of Hebei Medical University,Shijia Zhuang, Hebei, China[23]Huaihe Hospital of Henan University,Kaifeng, Henan, China[24]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang, Henan, China[25]The Third People's Hospital of Luoyang City,Luoyang, Henan, China[26]Xinxiang Central Hospital,Xinxiang, Henan, China[27]The First People's Hospital of Chenzhou City,Chenzhou, Hunan, China[28]Yueyang Second People's Hospital,Yueyang, Hunan, China[29]Zhuzhou Central Hospital,Zhuzhou, Hunan, China
研究目的:
The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.